Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018126317) VEGFR-2 CAR IMMUNE CELLS TO TREAT CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/126317 International Application No.: PCT/CA2018/050004
Publication Date: 12.07.2018 International Filing Date: 04.01.2018
IPC:
C12N 15/13 (2006.01) ,A61K 35/17 (2015.01) ,A61P 35/00 (2006.01) ,C07K 14/705 (2006.01) ,C07K 16/28 (2006.01) ,C07K 19/00 (2006.01) ,C12N 15/62 (2006.01) ,C12N 15/85 (2006.01) ,C12N 5/0783 (2010.01) ,C12N 5/10 (2006.01)
[IPC code unknown for C12N 15/13][IPC code unknown for A61K 35/17][IPC code unknown for A61P 35][IPC code unknown for C07K 14/705][IPC code unknown for C07K 16/28][IPC code unknown for C07K 19][IPC code unknown for C12N 15/62][IPC code unknown for C12N 15/85][IPC code unknown for C12N 5/0783][IPC code unknown for C12N 5/10]
Applicants:
HELIX BIOPHARMA CORPORATION [CA/CA]; 9120 Leslie Street, Suite 205 Richmond Hill, Ontario L4B 3J9, CA
Inventors:
CHAO, Heman; CA
WONG, Wah Yau; CA
TIAN, Baomin; CA
UGER, Marni Diane; CA
Agent:
BARTOSZEWICZ, Lola A.; CA
CHEUNG, Sumei; CA
LOWTHERS, Erica L.; CA
MCMANUS, Kimberly A.; CA
SABETA, Tony; CA
SINDEN, Kitt; CA
Priority Data:
62/442,64905.01.2017US
62/480,71203.04.2017US
62/491,64328.04.2017US
62/535,33021.07.2017US
Title (EN) VEGFR-2 CAR IMMUNE CELLS TO TREAT CANCERS
(FR) CELLULES IMMUNITAIRES CAR-VEGFR-2 POUR LE TRAITEMENT DES CANCERS
Abstract:
(EN) Compositions and methods for treating cancer in humans are provided using CARs. The invention includes engineered CARs (chimeric receptor antigens) and genetically modified immune cells that express such a CAR with a high affinity for VEGFR. More specifically, the cells are CAR-T cells recognizing VEGFR-2 on solid tumors, uses thereof, compositions thereof and methods of making. The invention includes therapeutic methods to treat VEGFR-2 dependent cancers targeting tumor angiogenesis. A chimeric antigen receptor (CAR) that binds to VEGFR-2, an epitope or fragment thereof, or a variant thereof.
(FR) L'invention concerne des compositions et des procédés pour le traitement du cancer chez l'être humain utilisant des récepteurs CAR. L'objet de l'invention comprend des récepteurs CAR (récepteurs antigéniques chimériques) modifiés et des cellules immunitaires génétiquement modifiées qui expriment un tel récepteur CAR présentant une affinité élevée pour le VEGFR. Plus spécifiquement, les cellules sont des lymphocytes T-CAR reconnaissant le VEGFR-2 sur les tumeurs solides, leurs utilisations, des compositions en comprenant et leurs procédés de fabrication. L'invention concerne des méthodes thérapeutiques pour le traitement de cancers dépendant du VEGFR-2 ciblant l'angiogenèse tumorale. L'invention concerne un récepteur antigénique chimérique (CAR) qui se lie au VEGFR-2, un épitope ou un fragment de celui-ci, ou un variant de celui-ci.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)